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Abstract
This is a report of a meeting sponsored by MundiPharma International to identify ways to exploit
the cerebrospinal fluid system pharmacologically, for more effective management and prevention
of primary and metastatic CNS tumors.
Background
Thirty investigators from numerous cancer research cent-
ers in the United States and Europe were convened by
conference organizer, Michael Glantz (University of Utah
School of Medicine – Huntsman Cancer Institute), to
brainstorm the understanding of novel mechanisms, and
the development of new paradigms involving the cerebro-
spinal fluid (CSF) system, for thwarting the spread and
improving the treatment of nervous system cancers. This
retreat brought oncologists and clinical neuroscientists to
St. Thomas, Virgin Islands on February 22–24, 2007. The
conference, entitled 'The Science of Prevention: New Insights
into the Importance of Intra-CSF Prophylaxis', was organized
around several provocative theses to stimulate discussion
of novel ways to treat, and even prevent, brain and menin-
geal tumors.
Discussion
Pathophysiogically and pharmacologically, the CSF is an
important circulatory system in the brain and spinal cord
that, on the one hand disseminates malignant cells, but
on the other hand might be harnessed to distribute correc-
tive chemotherapeutic drugs. As knowledge of the CSF
system increases, so do the opportunities for managing
brain cancer. Successful CSF prophylaxis for medulloblas-
toma and acute leukemia could well serve as a paradigm
for more effective treatment of lymphomas. Conference
introductory keynotes by Ching-Hon Pui (St. Jude Chil-
dren's Research Hospital) and Eckhard Thiel (Charite Uni-
versity Medicine Berlin) provided historical perspective
and state-of-the-art reviews on acute leukemia and non-
Hodgkin's lymphoma. Michael Glantz then addressed the
feasibility of a randomized, controlled trial of CSF proph-
ylaxis in patients with high-risk non-Hodgkin's lym-
phoma. The treatment-refractory glioblastoma
multiforme, in dire need of a new therapeutic model, was
addressed by Lawrence Recht (Stanford University Medi-
cal School) who analyzed gliomagenesis in the context of
growth factor effects on cancer stem cells in the subven-
tricular zone. Utilizing new basic science information,
Glantz then proposed a phase II trial incorporating intra-
CSF chemotherapy into the initial treatment of patients
with newly diagnosed glioblastoma multiforme.
Three decades of experience with neoplastic meningitis
(NM) has afforded many clinical insights on treatment,
but cures remain exceedingly rare, and controversy per-
sists regarding the most basic tenets. Marc Chamberlain
(Fred Hutchinson Cancer Center) reviewed prognostic
variables within subgroups of patients with solid tumor
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neoplastic meningitis, and urged tumor-specific strategies
for CSF-directed therapy. However, the whole concept of
intrathecal chemotherapy as a treatment for solid tumor
NM was questioned by Willem Boogerd (Netherlands
Cancer Institute) who emphasized the urgent need for a
randomized clinical trial to address this issue, and pre-
sented such a proposal on behalf of the European Organ-
isation for Research and Treatment of Cancer (EORTC).
The rationale and techniques for treating malignant cells
in CSF were discussed by William Shapiro (Barrow Neuro-
logical Institute), while the expectations for significantly
improving survival in solid-tumor patients were outlined
by Stuart Grossman (Johns Hopkins Medical Institu-
tions). Conrad Johanson (Brown University – Warren
Alpert Medical School) introduced the potential role of
pharmacologically modifying choroid plexus function to
treat or prevent cancer spread along the ventriculo-sub-
arachnoid CSF system. Recognizing the limitations of CSF
cytology and magnetic resonance scanning, Glantz out-
lined the need for more sensitive techniques to diagnose
CSF malignancies and evaluate treatment outcomes. The
importance of novel markers for diagnosing and monitor-
ing responses in NM and lymphomatous meningitis was
extensively treated by Morris Groves (M.D. Anderson
Cancer Center) and Wyndham Wilson (National Cancer
Institute).
The final session of the conference was both practical and
visionary. Clinical trials, both newly completed and pro-
jected, were discussed. New insights for protecting against
brain metastases (including lung and breast cancer) were
delineated by Wallace Akerley (University of Utah School
of Medicine – Huntsman Cancer Institute), Frankie Hol-
mes (Baylor College of Medicine) and Ricardo Soffietti
(University of Turin). Gudrun Fleischhack (University
Children's Hospital, Bonn) introduced opportunities for
pediatric primary brain tumor initiatives, while Ulrich
Herrlinger (University of Bonn) discussed primary central
nervous system lymphoma. Randy Jensen (University of
Utah School of Medicine – Huntsman Cancer Institute)
reviewed the evidence in favor of post-neurosurgical
prophylaxis. Finally, Jennifer Smith (Geron Corp) treated
statistical issues in designing critical trials, including iden-
tifying predictive and prognostic markers. She also offered
advice on clinical trial proposals developed during the
conference.
Conclusion
This Science of Prevention conference was the first of its
kind to focus on the CSF as a medium around which to
marshall research and clinical strategies for preventing
and treating brain cancer. Brain tumor development or
spread, from both the pathologic and the pharmacologic
point of view, is critically dependent upon functional rela-
tionships between CSF dynamics and brain metabolism.
Considerably more information is needed about CSF-bor-
dering cells (e.g., choroid plexus, ependyma and the
arachnoid) in order to more effectively thwart dissemina-
tion of cancer cells throughout the CSF and interstitial
fluid compartments. Also, analysis of primary brain
tumor development in the subventricular zone deserves
more attention as a site for modulating (by growth factors
and antagonists) stem cell oncogenicity. The efficacy of
intrathecal  versus  combined intrathecal and systemic
administration of chemotherapeutic drugs also merits
more attention. Clearly new CSF markers and diagnostic
techniques are essential for improving disease identifica-
tion and monitoring response to therapy in a class of dis-
eases which continues to challenge oncologists,
neurologists, neurosurgeons, basic scientists, and, most
especially, patients. As a result of this conference, the
rationale for expanding the intra-CSF prophylaxis
approach to brain and meningeal tumors has now been
more sharply defined.
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